Frequent silencing of the candidate tumor suppressor TRIM58 by promoter methylation in early-stage lung adenocarcinoma

In this study, we aimed to identify novel drivers that would be epigenetically altered through aberrant methylation in early-stage lung adenocarcinoma (LADC), regardless of the presence or absence of tobacco smoking-induced epigenetic field defects. Through genome-wide screening for aberrantly methylated CpG islands (CGIs) in 12 clinically uniform, stage-I LADC cases affecting six non-smokers and six smokers, we identified candidate tumor-suppressor genes (TSGs) inactivated by hypermethylation. Through systematic expression analyses of those candidates in panels of additional tumor samples and cell lines treated or not treated with 5-aza-deoxycitidine followed by validation analyses of cancer-specific silencing by CGI hypermethylation using a public database, we identified TRIM58 as the most prominent candidate for TSG. TRIM58 was robustly silenced by hypermethylation even in early-stage primary LADC, and the restoration of TRIM58 expression in LADC cell lines inhibited cell growth in vitro and in vivo in anchorage-dependent and -independent manners. Our findings suggest that aberrant inactivation of TRIM58 consequent to CGI hypermethylation might stimulate the early carcinogenesis of LADC regardless of smoking status; furthermore, TRIM58 methylation might be a possible early diagnostic and epigenetic therapeutic target in LADC.

[1]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[2]  L. Tanoue,et al.  The new lung cancer staging system. , 2009, Chest.

[3]  Mihaela Campan,et al.  Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer , 2008, Molecular Cancer.

[4]  Kemp H. Kernstine,et al.  DNA methylation biomarkers for lung cancer , 2011, Tumor Biology.

[5]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[6]  J. Mackay,et al.  Trim58 degrades Dynein and regulates terminal erythropoiesis. , 2014, Developmental cell.

[7]  Kimberly D. Siegmund,et al.  DNA Methylation Changes in Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, and Lung Adenocarcinoma , 2011, PloS one.

[8]  L. van Neste,et al.  Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. , 2014, Carcinogenesis.

[9]  Antoni Rosell,et al.  A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer , 2016, Clinical Cancer Research.

[10]  Q. Tao,et al.  FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. , 2013, Carcinogenesis.

[11]  Ahmet Selim Yurdakul,et al.  The New Lung Cancer Staging System , 2010 .

[12]  P. Bunn,et al.  Recent clinical advances in lung cancer management. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. L. R. D. Christenson,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2012 .

[14]  K. Masuda,et al.  Tumor-promoting function and prognostic significance of the RNA-binding protein T-cell intracellular antigen-1 in esophageal squamous cell carcinoma , 2016, Oncotarget.

[15]  S. Toyooka,et al.  Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. , 2006, Cancer research.

[16]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[17]  Y. S. Malik,et al.  Epigenetic Regulation of Dpp6 Expression by Dnmt3b and Its Novel Role in the Inhibition of RA Induced Neuronal Differentiation of P19 Cells , 2013, PloS one.

[18]  Fang Zheng,et al.  Aberrant methylation of TRIM58 in hepatocellular carcinoma and its potential clinical implication. , 2016, Oncology reports.

[19]  T. Down,et al.  Genome Wide Analysis of Acute Myeloid Leukemia Reveal Leukemia Specific Methylome and Subtype Specific Hypomethylation of Repeats , 2012, PloS one.

[20]  S. Hirohashi,et al.  Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. , 2005, Human molecular genetics.

[21]  S. Hirohashi,et al.  Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. , 2006, Cancer research.

[22]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[23]  John D Minna,et al.  Molecular biology of lung cancer: clinical implications. , 2002, Clinics in chest medicine.

[24]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.